FULC — Fulcrum Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1680581 ·
Last close
$6.76
Market Cap
$450.44M
52W High
$8.84
52W Low
$5.88
ADV30
681,586
Next earnings
2026-04-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,186,000 | -18,891,000 | 346,770,000 | 50,261,000 | 13,467,000 |
| Dec 2025 | 0 | — | -22,693,000 | -20,334,000 | 366,284,000 | 197,533,000 | 17,284,000 |
| Sep 2025 | 0 | — | -21,858,000 | -19,595,000 | 214,858,000 | 47,078,000 | 16,492,000 |
| Jun 2025 | 0 | — | -19,815,000 | -17,296,000 | 228,838,000 | 42,588,000 | 14,460,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,558,000
Investing CF
$-96,714,000
Financing CF
$168,355,000
CapEx
$-488,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.15
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-613,169,000
Inventory
—
Receivables
$1,776,000
ST Investments
$283,055,000
EBIT TTM
$-86,552,000
Pretax Income TTM
$-76,116,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,769,000 | -74,880,000 | 366,284,000 | 17,284,000 | — | -60,065,000 |
| Dec 2024 | 80,000,000 | -19,834,000 | -9,725,000 | 260,718,000 | 17,684,000 | — | -2,218,000 |
| Dec 2023 | 2,805,000 | -110,664,000 | -97,335,000 | 257,694,000 | 22,501,000 | — | -90,965,000 |
| Dec 2022 | 6,342,000 | -112,134,000 | -109,871,000 | 226,685,000 | 27,743,000 | — | -97,050,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.33
Max Pain — expiry 2026-06-18
max pain strike: $7.00 · spot: $6.76 · call oi: 5,413 · put oi: 1,559
Expected Move to 2026-06-18:
±$1.38
(20.34%) —
implied range
$5.39 –
$8.14
· ATM straddle on $7.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FBRX | Forte Biosciences, Inc. | $449.31M | $21.94 | — |
| CTNM | Contineum Therapeutics, Inc. | $448.32M | $13.70 | — |
| UPB | Upstream Bio, Inc. | $446.79M | $8.21 | — |
| ADCT | ADC Therapeutics SA | $446.44M | $3.51 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $456.91M | $28.75 | — |
News headlines (Yahoo Finance, 1h cache)
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)
2026-05-20 13:35 · Yahoo
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-08 20:30 · Yahoo
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
2026-04-28 07:02 · Yahoo
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary
2026-04-27 16:46 · Yahoo
Fulcrum Therapeutics Q1 Earnings Call Highlights
2026-04-27 15:45 · Yahoo
Fulcrum (FULC) Q1 2026 Earnings Transcript
2026-04-27 15:41 · Yahoo
Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations
2026-04-27 15:08 · Yahoo
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
2026-04-27 11:00 · Yahoo
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
2026-04-27 10:55 · Yahoo
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
2026-04-20 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.